Product Description
Mechanisms of Action: Fibrinolysis Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Topical,Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Austria | Belgium | Brazil | Bulgaria | Canada | China | Colombia | Croatia | Czech | Denmark | France | Germany | Greece | Hong Kong | Hungary | India | Ireland | Italy | Jordan | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | New Zealand | Norway | Poland | Singapore | Slovenia | Spain | Sweden | Taiwan | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay
Approved Indications: None
Known Adverse Events: None
Company: Ethicon
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Bulgaria, Canada, China, France, Germany, Hungary, Romania, Serbia, Spain, Sweden, United Kingdom, United States
Active Clinical Trial Count: 12
Highest Development Phases
Phase 3: Adenocarcinoma|Cardiac Arrest|Gastrointestinal Cancer|Injuries/wounds Unspecified
Phase 2: Diabetic Foot|Intervertebral Disc Degeneration
Phase 1: COVID-19
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2024-513151-33-00 | P2 |
Unknown Status |
Unknown |
2027-06-22 |
|
2019-004657-89 | P3 |
Unknown status |
Cardiac Arrest |
2025-12-14 |
|
CM-TS01 | P3 |
Not yet recruiting |
Injuries/wounds Unspecified |
2025-07-31 |
|
BIOS-16-001 | P3 |
Recruiting |
Cardiac Arrest |
2025-06-01 |